Malignant Glioma DIPG
Conditions
Interventions
The patient is intradermally injected with 0.5 -2 mg of the HLA-A2402-restricted, 9-mer modified WT1 peptide (p235-243:CYTWNQMN), the HLA A0201 restricted (mp126-134 RMFPNAPYL) modified WT1 peptide an
Sponsors
Osaka university graduate school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically confirmed high grade glioma except diffuse intrinsic pontine glioma 2) WT1 pathologically positive in HGG. 3) Recurrence confirmed with RANO criteria including radiological evaluations. 4) From 1 month after completion of radiotherapy 5) ECOG-PS: 0-3 6) Age:under 15 years old 7) HLA-A*24:02 and / or HLA-A*02:01 8) adequate organ functions Neutrophils > 1,000 Platelets > 25, 000 Hb > 6.5 sCr : Age normal level upper limit 3 times T-Bil : Age normal level upper limit 3 times AST / ALT < 200 IU/L 9) Informed consent from legal guardian
Exclusion criteria
Exclusion criteria: 1) active infectious diseases 2) Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 3) Other severe problems unsuitable for this study active infectious diseases 4) Active other cancers except for carcinoma in situ treated completely 5) Past history of Myeloproliferative diseases, MSD 6) Received allogeneic stem cell transplantation 7) Severe Psychological Problems
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One year survival ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectiveness using RANO criteria, Safty, immunomonitaring to WT1 peptide | — |
Countries
Japan
Contacts
Public ContactYoshiko Hashii
Osaka university graduate school of medicine Pediatrics
Outcome results
None listed